UNIGE document Scientific Article
previous document  unige:1688  next document
add to browser collection
Title

Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?

Author
Published in Nature Reviews Rheumatology. 2008, vol. 4, no. 11, p. 572-3
Abstract Interleukin (IL)-6 is a pleiotropic cytokine that has a major role in inflammatory diseases. The results of two recently published clinical trials that used different study designs demonstrated that tocilizumab, a humanized monoclonal antibody that targets the binding of IL-6 to its receptor, improved the clinical and biological signs of disease activity in both rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis. Adverse events included a higher risk of infections, transient elevation of liver aminotransferases, higher cholesterol levels, and a few allergic reactions. Future studies should investigate the long-term efficacy (clinical and structural) and safety of tocilizumab, including its effect on lipid levels.
Keywords Clinical trialsInterleukin-6Rheumatoid arthritisSystemic-onset juvenile idiopathic arthritisTocilizumab
Identifiers
PMID: 18779846
Full text
Structures
Research group Mécanisme de l'inflammation articulaire (44)
Citation
(ISO format)
GABAY, Cem. Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?. In: Nature Reviews Rheumatology, 2008, vol. 4, n° 11, p. 572-3. doi: 10.1038/ncprheum0900 https://archive-ouverte.unige.ch/unige:1688

355 hits

1 download

Update

Deposited on : 2009-05-22

Export document
Format :
Citation style :